Cannabidiol and CBD Health Products Pumping Industrial Hemp Sales As Scientific & Clinical Studies Underscore CBD Potential

As state legislators come to grips with the surge in CBD Oil bills aimed at Medical Marijuana, retailers nationwide are looking for a legal, higher-quality product to sell in the marketplace. As it turns out, CBD is truly one of the most exciting new supplements that people nationwide can get their hands on. In the coming years CBD may well become the most common supplement for those who want an all-natural alternative to pharmaceuticals. I a recent observation of ArisiTol CBD users, over 85% of those asked had stated that they do not wish to ‘get high’ as it were; the primary interests were ease of use, drug interactions and cost.

TwinFalls Biotech, LLC is the maker of the unique ArisiTol CBD lozenge tablets, designed like a breath mint. Company CEO, David Mouser commented about the current market; “Ultra low THC from imported industrial hemp, if tested properly, can provide an amazing amount of positive change for a very reasonable price; which is actually the largest driving force behind Generation X and Baby Boomer sales with our product.

People have seen the scientific information. Now, more than ever, they are ready to try CBD; they want to see some positive results for themselves. As more people are reaching retirement, we expect to see a surge in sales between now and 2020. This is a critical age where people need to take time, release stress and fix their pain and inflammation. This is a great time for ArisiTol, and a great time to dig in and really look at the quality of what’s out there. Most people get our free trials and I see them immediately call and make a switch.”

While there are some questions on a handful of inferior CBD products, Industry Watchdog ICOMR is heavy on testing, and light on the propaganda. Consumer interest is high as their recent CBD Product Reviews made national news distribution. In a recent Press Release, other marketers were highlighted, CNN carried the wire:

Cannabis Science Inc. (OTCQB: CBIS) a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to provide a guidance report on its current pre-clinical drug development programs underway, beginning with the scientific cannabis cultivation programs in Europe and North America, testing multiple cannabis strains for multiple critical ailments. Mr. Mario S. Lap, Director and President of European Operations, stated, ” The Company’s efforts in Spain compliment Cannabis Science’s plans in Canada and the Company’s current, pre-clinical collaboration with the Institute for Research, Hospitalization and Health Care on Ageing (INRCA) in Italy, where the Company is testing toxicity and efficacy of cannabinoid formulations for neurobehavioral diseases including sleep disorders.”

Medical Marijuana Inc. (OTC Pink: MJNA) announce that one of its investment portfolio companies, KannaLife Sciences, Inc. (“KannaLife”), is the subject of this tremendous amount of mainstream news coverage. MJNA directly owns 16.70% of KannaLife’s capital stock. KannaLife co-founder Thoma Kikis stated in a recent interview, “On the FDA drug pipeline, we are focused on treating diseases that affect the brain.” Kikis went on to explain that “CTE is a concussion-induced disease with long-term effects mostly suffered by football, hockey, soccer players and boxers.” CTE is defined by Boston University as: “A progressive degenerative disease of the brain found in athletes (and others) with a history of repetitive brain trauma, including symptomatic concussions as well as asymptomatic subconcussive hits to the head.” KannaLife is leading the industry by tackling major issues that plague professional sports and other athletes including the NFL’s mission to protect former and current players from CTE.